Agency Information Collection Activities; Proposed Collection; Comment Request; Exceptions or Alternatives to Labeling Requirements for Products Held by the Strategic National Stockpile, 23584-23587 [2017-10535]
Download as PDF
23584
Federal Register / Vol. 82, No. 98 / Tuesday, May 23, 2017 / Notices
in furtherance of FDA’s goal of ensuring
transparency regarding the
qualifications of individuals selected to
serve on FDA advisory committees, and
in recognition that individual advisory
committee members are best situated to
evaluate the confidentiality of
information contained in their CVs,
including any considerations raised by
their relationships and agreements with
third parties, FDA will now be requiring
that all CVs submitted as part of the
nomination process for positions on
FDA advisory committees be
accompanied by a written consent form
stating that, if the nominee is accepted
as a member of an FDA advisory
committee, the nominee consents to the
publication of the nominee’s CV to
FDA’s Web site, without FDA removing
or redacting any information. The
consent form requires that the nominee
affirm that the CV does not include any
confidential information, including
information pertaining to third parties
that the nominee is not permitted to
disclose. A nominee will be required to
submit a signed consent form as a part
of the nomination package in order for
the nomination to be considered
complete.
All nominations for new advisory
committee members will be required to
be submitted through FDA’s Web site at
https://accessdata.test.fda.gov/scripts/
FACTRSPortal/FACTRS/index.cfm, or
any successor system, and the
submission will be required to be
accompanied by the consent form, on or
after the date of OMB approval for this
information collection.
In the Federal Register of February 6,
2017 (82 FR 9383), we published a 60-
day notice requesting public comment
on the proposed collection of
information. One comment was received
in support of the information collection
and recommended no changes to the
Agency’s burden estimate. On our own
initiative, however, we have revised the
estimate provided in our 60 day notice
to reflect an increase of 23.5 burden
hours and 94 responses. While we
believe our original burden estimate
accurately reflects the time burden
associated with providing the specific
data elements, but we have increased
the number of respondents to the
collection to include Industry
Representative members of FDA
advisory committees.
We therefore estimate the burden of
the information collection as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
21 CFR part 14; subpart E—members of advisory
committees
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
Total annual
responses
Total hours
Advisory Committee Membership Nominations ...................
583
1
583
0.25
(15 minutes)
145.75
Representative Member Submission of Updated Information ....................................................................................
64
1
64
0.25
(15 minutes)
16.0
Total ..............................................................................
........................
........................
647
........................
161.75
sradovich on DSK3GMQ082PROD with NOTICES
1 There
are no capital or operating and maintenance costs associated with the information collection.
Based on a review of data, we
received 638 nominations for
membership to FDA advisory
committees in Fiscal Year (FY) 2011; we
received 603 nominations in FY 2012;
we received 622 in FY 2013; we
received 545 in FY 2014; and we
received 505 nominations in FY 2015.
By averaging the number of nominations
received annually over the past 5 years,
we estimate there are approximately 583
respondents to the information
collection. We estimate it takes
respondents 15 minutes to complete an
initial nomination, where
accompanying documentation is already
available or has been prepared in
advance by respondents. Multiplying 15
minutes (0.25) by the number of
respondents to the information
collection (583) equals 145.75 annual
burden hours.
We have also included a burden
estimate for members who currently
serve on FDA advisory committees who
are not Special Government and Regular
Government Employees and who must
submit an updated CV and an executed/
completed consent form annually.
Currently there are 64 authorized
positions for these Representative
VerDate Sep<11>2014
21:15 May 22, 2017
Jkt 241001
members, mostly Industry
representatives. While some positions
are vacant, we anticipate the positions
will be filled during the year. The
request for the updated CV and consent
will be made through email
communications by the Designated
Federal Officer of the committee. We
anticipate that the burden to the
respondent will be the same as that for
new nominations. We estimate each
response will require 15 minutes (0.25)
for a total of 16 annual hours.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: May 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
HHS.
[FR Doc. 2017–10531 Filed 5–22–17; 8:45 am]
BILLING CODE 4164–01–P
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
Food and Drug Administration
[Docket No. FDA–2010–N–0588]
Agency Information Collection
Activities; Proposed Collection;
Comment Request; Exceptions or
Alternatives to Labeling Requirements
for Products Held by the Strategic
National Stockpile
AGENCY:
ACTION:
Food and Drug Administration,
Notice.
The Food and Drug
Administration (FDA or Agency) is
announcing an opportunity for public
comment on the proposed collection of
certain information by the Agency.
Under the Paperwork Reduction Act of
1995 (PRA), Federal Agencies are
required to publish notice in the
Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information, and
to allow 60 days for public comment in
response to the notice. This notice
SUMMARY:
E:\FR\FM\23MYN1.SGM
23MYN1
Federal Register / Vol. 82, No. 98 / Tuesday, May 23, 2017 / Notices
solicits comments on the information
collection requirements related to the
exceptions or alternatives to labeling
requirements for products held by the
Strategic National Stockpile (SNS).
DATES: Submit either electronic or
written comments on the collection of
information by July 24, 2017.
ADDRESSES: You may submit comments
as follows. Please note that late,
untimely filed comments will not be
considered. Electronic comments must
be submitted on or before July 24, 2017.
The https://www.regulations.gov
electronic filing system will accept
comments until midnight Eastern Time
at the end of July 24, 2017. Comments
received by mail/hand delivery/courier
(for written/paper submissions) will be
considered timely if they are
postmarked or the delivery service
acceptance receipt is on or before that
date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
sradovich on DSK3GMQ082PROD with NOTICES
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Division of
Dockets Management (HFA–305), Food
and Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Division of Dockets
Management, FDA will post your
comment, as well as any attachments,
VerDate Sep<11>2014
21:15 May 22, 2017
Jkt 241001
except for information submitted,
marked and identified, as confidential,
if submitted as detailed in
‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2010–N–0588 for ‘‘Exceptions or
Alternatives to Labeling Requirements
for Products Held by the Strategic
National Stockpile.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Division of Dockets Management
between 9 a.m. and 4 p.m., Monday
through Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Division of Dockets
Management. If you do not wish your
name and contact information to be
made publicly available, you can
provide this information on the cover
sheet and not in the body of your
comments and you must identify this
information as ‘‘confidential.’’ Any
information marked as ‘‘confidential’’
will not be disclosed except in
accordance with 21 CFR 10.20 and other
applicable disclosure law. For more
information about FDA’s posting of
comments to public dockets, see 80 FR
56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Division of Dockets
Management, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852.
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
23585
FOR FURTHER INFORMATION CONTACT:
JonnaLynn Capezzuto, Office of
Operations, Food and Drug
Administration, Three White Flint
North, 10A63, 11601 Landsdown St.,
North Bethesda, MD 20852, 301–796–
3794.
Under the
PRA (44 U.S.C. 3501–3520), Federal
Agencies must obtain approval from the
Office of Management and Budget
(OMB) for each collection of
information they conduct or sponsor.
‘‘Collection of information’’ is defined
in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests
or requirements that members of the
public submit reports, keep records, or
provide information to a third party.
Section 3506(c)(2)(A) of the PRA (44
U.S.C. 3506(c)(2)(A)) requires Federal
Agencies to provide a 60-day notice in
the Federal Register concerning each
proposed collection of information,
including each proposed extension of an
existing collection of information,
before submitting the collection to OMB
for approval. To comply with this
requirement, FDA is publishing notice
of the proposed collection of
information set forth in this document.
With respect to the following
collection of information, FDA invites
comments on these topics: (1) Whether
the proposed collection of information
is necessary for the proper performance
of FDA’s functions, including whether
the information will have practical
utility; (2) the accuracy of FDA’s
estimate of the burden of the proposed
collection of information, including the
validity of the methodology and
assumptions used; (3) ways to enhance
the quality, utility, and clarity of the
information to be collected; and (4)
ways to minimize the burden of the
collection of information on
respondents, including through the use
of automated collection techniques,
when appropriate, and other forms of
information technology.
SUPPLEMENTARY INFORMATION:
Exceptions or Alternatives to Labeling
Requirements for Products Held by the
Strategic National Stockpile—OMB
Control Number 0910–0614—Extension
Under the Public Health Service Act
(PHS Act), the Department of Health
and Human Services stockpiles medical
products that are essential to the health
security of the Nation (see the PHS Act,
42 U.S.C. 247d–6b). This collection of
medical products for use during
national health emergencies, known as
the SNS, is to ‘‘provide for the
emergency health security of the United
States, including the emergency health
security of children and other
E:\FR\FM\23MYN1.SGM
23MYN1
23586
Federal Register / Vol. 82, No. 98 / Tuesday, May 23, 2017 / Notices
vulnerable populations, in the event of
a bioterrorist attack or other public
health emergency.’’
It may be appropriate for certain
medical products that are or will be
held in the SNS to be labeled in a
manner that would not comply with
certain FDA labeling regulations given
their anticipated circumstances of use in
an emergency. However, noncompliance
with these labeling requirements could
render such products misbranded under
section 502 of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 352).
Under 21 CFR 201.26, 610.68,
801.128, and 809.11 (§§ 201.26, 610.68,
801.128, and 809.11), the appropriate
FDA Center Director may grant a request
for an exception or alternative to certain
regulatory provisions pertaining to the
labeling of human drugs, biological
products, medical devices, and in vitro
diagnostics that currently are or will be
included in the SNS if certain criteria
are met. The appropriate FDA Center
Director may grant an exception or
alternative to certain FDA labeling
requirements if compliance with these
labeling requirements could adversely
affect the safety, effectiveness, or
availability of products that are or will
be included in the SNS. An exception
or alternative granted under the
regulations may include conditions or
safeguards so that the labeling for such
products includes appropriate
information necessary for the safe and
effective use of the product given the
product’s anticipated circumstances of
use. Any grant of an exception or
alternative will only apply to the
specified lots, batches, or other units of
medical products in the request. The
appropriate FDA Center Director may
also grant an exception or alternative to
the labeling provisions specified in the
regulations on his or her own initiative.
Under §§ 201.26(b)(1)(i) (human drug
products), 610.68(b)(1)(i) (biological
products), 801.128(b)(1)(i) (medical
devices), and 809.11(b)(1)(i) (in vitro
diagnostic products for human use), an
SNS official or any entity that
manufactures (including labeling,
packing, relabeling, or repackaging),
distributes, or stores such products that
are or will be included in the SNS may
submit, with written concurrence from
a SNS official, a written request for an
exception or alternative to certain
labeling requirements to the appropriate
FDA Center Director. Except when
initiated by an FDA Center Director, a
request for an exception or alternative
must be in writing and must:
• Identify the specified lots, batches,
or other units of the affected product;
• Identify the specific labeling
provisions under the regulations that are
the subject of the request;
• Explain why compliance with the
specified labeling provisions could
adversely affect the safety, effectiveness,
or availability of the product subject to
the request;
• Describe any proposed safeguards
or conditions that will be implemented
so that the labeling of the product
includes appropriate information
necessary for the safe and effective use
of the product given the anticipated
circumstances of use of the product;
• Provide copies of the proposed
labeling of the specified lots, batches, or
other units of the affected product that
will be subject to the exception or
alternative; and
• Provide any other information
requested by the FDA Center Director in
support of the request.
If the request is granted, the
manufacturer may need to report to FDA
any resulting changes to the new drug
application, biologics license
application, premarket approval
application, or premarket notification
(510(k)) in effect, if any. The submission
and grant of an exception or an
alternative to the labeling requirements
specified in the regulations may be used
to satisfy certain reporting obligations
relating to changes to product
applications under §§ 314.70, 601.12,
814.39 and 807.81 (21 CFR 314.70
(human drugs), 21 CFR 601.12
(biological products), 21 CFR 814.39
(medical devices subject to premarket
approval), or 21 CFR 807.81 (medical
devices subject to 510(k) clearance
requirements)). The information
collection provisions in §§ 314.70,
601.12, 807.81, and 814.39 have been
approved under OMB control numbers
0910–0001, 0910–0338, 0910–0120, and
0910–0231, respectively. On a case-bycase basis, the appropriate FDA Center
Director may also determine when an
exception or alternative is granted that
certain safeguards and conditions are
appropriate, such as additional labeling
on the SNS products, so that the
labeling of such products would include
information needed for safe and
effective use under the anticipated
circumstances of use.
Respondents to this collection of
information are entities that
manufacture (including labeling,
packing, relabeling, or repackaging),
distribute, or store affected SNS
products. Based on data from fiscal
years 2014 and 2015, FDA estimates an
average of one request annually for an
exception or alternative received by
FDA. FDA estimates an average of 24
hours preparing each request. The
average burden per response for each
submission is based on the estimated
time that it takes to prepare a
supplement to an application, which
may be considered similar to a request
for an exception or alternative. To the
extent that labeling changes not already
required by FDA regulations are made
in connection with an exception or
alternative granted under the
regulations, FDA is estimating one
occurrence annually in the event FDA
would require any additional labeling
changes not already covered by FDA
regulations. FDA estimates 8 hours to
develop and revise the labeling to make
such changes. The average burden per
response for each submission is based
on the estimated time to develop and
revise the labeling to make such
changes.
FDA estimates the burden of this
collection of information as follows:
TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1
sradovich on DSK3GMQ082PROD with NOTICES
201.26(b)(1)(i),
809.11(b)(1)(i)
201.26(b)(1)(i),
809.11(b)(1)(i)
610.68(b)(1)(i), 801.128(b)(1)(i), and
...................................................................
610.68(b)(1)(i), 801.128(b)(1)(i), and
...................................................................
Total ..............................................................................
1 There
Number of
responses per
respondent
Number of
respondents
21 CFR section
Average
burden per
response
(in hours)
Total annual
responses
1
1
1
24
24
1
1
1
8
8
........................
........................
........................
........................
32
are no capital costs or operating and maintenance costs associated with this collection of information.
VerDate Sep<11>2014
21:15 May 22, 2017
Jkt 241001
PO 00000
Total hours
Frm 00066
Fmt 4703
Sfmt 4703
E:\FR\FM\23MYN1.SGM
23MYN1
Federal Register / Vol. 82, No. 98 / Tuesday, May 23, 2017 / Notices
applicable, the business or professional
affiliation of the interested person.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.846, Arthritis,
Musculoskeletal and Skin Diseases Research,
National Institutes of Health, HHS)
Dated: May 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning,
Legislation, and Analysis.
[FR Doc. 2017–10535 Filed 5–22–17; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Arthritis and
Musculoskeletal and Skin Diseases:
Notice of Meeting
sradovich on DSK3GMQ082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Arthritis and Musculoskeletal
and Skin Diseases Advisory Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Arthritis and
Musculoskeletal and Skin Diseases Advisory
Council.
Date: June 21, 2017.
Open: 8:30 a.m. to 1:00 p.m.
Agenda: To discuss program policies and
issues.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Bethesda, MD
20892.
Closed: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, 31 Center Drive, Bethesda, MD
20892.
Contact Person: Melinda Nelson, Acting
Director, National Institute of Arthritis and
Musculoskeletal and Skin Diseases, Grants
Management Branch, 45 Center Drive,
Natcher Building, Room 5A49, Bethesda, MD
20892, (301) 594–3535, mn23z@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
VerDate Sep<11>2014
21:15 May 22, 2017
Jkt 241001
Dated: May 17, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10458 Filed 5–22–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Center for Complementary &
Integrative Health; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; NIH-DoD–VA Pain
Management Collaboratory—Coordinating
Center (U24).
Date: June 23, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott, 5151 Pooks Hill
Road, Bethesda, MD 20817.
Contact Person: Viatcheslav A
Soldatenkov, MD, Ph.D., Scientific Review
Officer, Office of Scientific Review, Division
of Extramural Activities, NCCIH/NIH, 6707
Democracy Blvd., Suite 401, Bethesda, MD
20892, soldatenkovv@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Integrative Health,
National Institutes of Health, HHS)
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
23587
Dated: May 17, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10454 Filed 5–22–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; U41 Genomic Resources.
Date: June 12, 2017.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, 5635 Fishers Lane, Conference
Room 3146, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, 5635 Fishers
Lane, Suite 4076, Bethesda, MD 20814, 301–
594–4280, mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: May 17, 2017.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–10455 Filed 5–22–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\23MYN1.SGM
23MYN1
Agencies
[Federal Register Volume 82, Number 98 (Tuesday, May 23, 2017)]
[Notices]
[Pages 23584-23587]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10535]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0588]
Agency Information Collection Activities; Proposed Collection;
Comment Request; Exceptions or Alternatives to Labeling Requirements
for Products Held by the Strategic National Stockpile
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing
an opportunity for public comment on the proposed collection of certain
information by the Agency. Under the Paperwork Reduction Act of 1995
(PRA), Federal Agencies are required to publish notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information, and
to allow 60 days for public comment in response to the notice. This
notice
[[Page 23585]]
solicits comments on the information collection requirements related to
the exceptions or alternatives to labeling requirements for products
held by the Strategic National Stockpile (SNS).
DATES: Submit either electronic or written comments on the collection
of information by July 24, 2017.
ADDRESSES: You may submit comments as follows. Please note that late,
untimely filed comments will not be considered. Electronic comments
must be submitted on or before July 24, 2017. The https://www.regulations.gov electronic filing system will accept comments until
midnight Eastern Time at the end of July 24, 2017. Comments received by
mail/hand delivery/courier (for written/paper submissions) will be
considered timely if they are postmarked or the delivery service
acceptance receipt is on or before that date.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand delivery/Courier (for written/paper
submissions): Division of Dockets Management (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Division of
Dockets Management, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2010-N-0588 for ``Exceptions or Alternatives to Labeling
Requirements for Products Held by the Strategic National Stockpile.''
Received comments, those filed in a timely manner (see ADDRESSES), will
be placed in the docket and, except for those submitted as
``Confidential Submissions,'' publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9
a.m. and 4 p.m., Monday through Friday.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will
review this copy, including the claimed confidential information, in
its consideration of comments. The second copy, which will have the
claimed confidential information redacted/blacked out, will be
available for public viewing and posted on https://www.regulations.gov.
Submit both copies to the Division of Dockets Management. If you do not
wish your name and contact information to be made publicly available,
you can provide this information on the cover sheet and not in the body
of your comments and you must identify this information as
``confidential.'' Any information marked as ``confidential'' will not
be disclosed except in accordance with 21 CFR 10.20 and other
applicable disclosure law. For more information about FDA's posting of
comments to public dockets, see 80 FR 56469, September 18, 2015, or
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Division of Dockets Management, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of
Operations, Food and Drug Administration, Three White Flint North,
10A63, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794.
SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal
Agencies must obtain approval from the Office of Management and Budget
(OMB) for each collection of information they conduct or sponsor.
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR
1320.3(c) and includes Agency requests or requirements that members of
the public submit reports, keep records, or provide information to a
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A))
requires Federal Agencies to provide a 60-day notice in the Federal
Register concerning each proposed collection of information, including
each proposed extension of an existing collection of information,
before submitting the collection to OMB for approval. To comply with
this requirement, FDA is publishing notice of the proposed collection
of information set forth in this document.
With respect to the following collection of information, FDA
invites comments on these topics: (1) Whether the proposed collection
of information is necessary for the proper performance of FDA's
functions, including whether the information will have practical
utility; (2) the accuracy of FDA's estimate of the burden of the
proposed collection of information, including the validity of the
methodology and assumptions used; (3) ways to enhance the quality,
utility, and clarity of the information to be collected; and (4) ways
to minimize the burden of the collection of information on respondents,
including through the use of automated collection techniques, when
appropriate, and other forms of information technology.
Exceptions or Alternatives to Labeling Requirements for Products Held
by the Strategic National Stockpile--OMB Control Number 0910-0614--
Extension
Under the Public Health Service Act (PHS Act), the Department of
Health and Human Services stockpiles medical products that are
essential to the health security of the Nation (see the PHS Act, 42
U.S.C. 247d-6b). This collection of medical products for use during
national health emergencies, known as the SNS, is to ``provide for the
emergency health security of the United States, including the emergency
health security of children and other
[[Page 23586]]
vulnerable populations, in the event of a bioterrorist attack or other
public health emergency.''
It may be appropriate for certain medical products that are or will
be held in the SNS to be labeled in a manner that would not comply with
certain FDA labeling regulations given their anticipated circumstances
of use in an emergency. However, noncompliance with these labeling
requirements could render such products misbranded under section 502 of
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352).
Under 21 CFR 201.26, 610.68, 801.128, and 809.11 (Sec. Sec.
201.26, 610.68, 801.128, and 809.11), the appropriate FDA Center
Director may grant a request for an exception or alternative to certain
regulatory provisions pertaining to the labeling of human drugs,
biological products, medical devices, and in vitro diagnostics that
currently are or will be included in the SNS if certain criteria are
met. The appropriate FDA Center Director may grant an exception or
alternative to certain FDA labeling requirements if compliance with
these labeling requirements could adversely affect the safety,
effectiveness, or availability of products that are or will be included
in the SNS. An exception or alternative granted under the regulations
may include conditions or safeguards so that the labeling for such
products includes appropriate information necessary for the safe and
effective use of the product given the product's anticipated
circumstances of use. Any grant of an exception or alternative will
only apply to the specified lots, batches, or other units of medical
products in the request. The appropriate FDA Center Director may also
grant an exception or alternative to the labeling provisions specified
in the regulations on his or her own initiative.
Under Sec. Sec. 201.26(b)(1)(i) (human drug products),
610.68(b)(1)(i) (biological products), 801.128(b)(1)(i) (medical
devices), and 809.11(b)(1)(i) (in vitro diagnostic products for human
use), an SNS official or any entity that manufactures (including
labeling, packing, relabeling, or repackaging), distributes, or stores
such products that are or will be included in the SNS may submit, with
written concurrence from a SNS official, a written request for an
exception or alternative to certain labeling requirements to the
appropriate FDA Center Director. Except when initiated by an FDA Center
Director, a request for an exception or alternative must be in writing
and must:
Identify the specified lots, batches, or other units of
the affected product;
Identify the specific labeling provisions under the
regulations that are the subject of the request;
Explain why compliance with the specified labeling
provisions could adversely affect the safety, effectiveness, or
availability of the product subject to the request;
Describe any proposed safeguards or conditions that will
be implemented so that the labeling of the product includes appropriate
information necessary for the safe and effective use of the product
given the anticipated circumstances of use of the product;
Provide copies of the proposed labeling of the specified
lots, batches, or other units of the affected product that will be
subject to the exception or alternative; and
Provide any other information requested by the FDA Center
Director in support of the request.
If the request is granted, the manufacturer may need to report to
FDA any resulting changes to the new drug application, biologics
license application, premarket approval application, or premarket
notification (510(k)) in effect, if any. The submission and grant of an
exception or an alternative to the labeling requirements specified in
the regulations may be used to satisfy certain reporting obligations
relating to changes to product applications under Sec. Sec. 314.70,
601.12, 814.39 and 807.81 (21 CFR 314.70 (human drugs), 21 CFR 601.12
(biological products), 21 CFR 814.39 (medical devices subject to
premarket approval), or 21 CFR 807.81 (medical devices subject to
510(k) clearance requirements)). The information collection provisions
in Sec. Sec. 314.70, 601.12, 807.81, and 814.39 have been approved
under OMB control numbers 0910-0001, 0910-0338, 0910-0120, and 0910-
0231, respectively. On a case-by-case basis, the appropriate FDA Center
Director may also determine when an exception or alternative is granted
that certain safeguards and conditions are appropriate, such as
additional labeling on the SNS products, so that the labeling of such
products would include information needed for safe and effective use
under the anticipated circumstances of use.
Respondents to this collection of information are entities that
manufacture (including labeling, packing, relabeling, or repackaging),
distribute, or store affected SNS products. Based on data from fiscal
years 2014 and 2015, FDA estimates an average of one request annually
for an exception or alternative received by FDA. FDA estimates an
average of 24 hours preparing each request. The average burden per
response for each submission is based on the estimated time that it
takes to prepare a supplement to an application, which may be
considered similar to a request for an exception or alternative. To the
extent that labeling changes not already required by FDA regulations
are made in connection with an exception or alternative granted under
the regulations, FDA is estimating one occurrence annually in the event
FDA would require any additional labeling changes not already covered
by FDA regulations. FDA estimates 8 hours to develop and revise the
labeling to make such changes. The average burden per response for each
submission is based on the estimated time to develop and revise the
labeling to make such changes.
FDA estimates the burden of this collection of information as
follows:
Table 1--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of Average burden
21 CFR section Number of responses per Total annual per response Total hours
respondents respondent responses (in hours)
----------------------------------------------------------------------------------------------------------------
201.26(b)(1)(i), 1 1 1 24 24
610.68(b)(1)(i),
801.128(b)(1)(i), and
809.11(b)(1)(i)................
201.26(b)(1)(i), 1 1 1 8 8
610.68(b)(1)(i),
801.128(b)(1)(i), and
809.11(b)(1)(i)................
-------------------------------------------------------------------------------
Total....................... .............. .............. .............. .............. 32
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
[[Page 23587]]
Dated: May 18, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-10535 Filed 5-22-17; 8:45 am]
BILLING CODE 4164-01-P